CLINICAL TRIALS PROFILE FOR TREMFYA
✉ Email this page to a colleague
All Clinical Trials for TREMFYA
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT03079531 ↗ | Open Label Study to Assess the Effect of Secukinumab in Moderate to Severe Papulopustular Rosacea | Completed | Anne Chang | Phase 1/Phase 2 | 2017-06-21 | This is a study to determine whether secukinumab is a potential therapy for those with papulopustular rosacea. We will observe whether this drug decreases the size and/or amount and severity of the pustules of those who suffer from rosacea. |
| NCT03649971 ↗ | A Study of Guselkumab in Participants With Familial Adenomatous Polyposis | Active, not recruiting | Janssen Research & Development, LLC | Phase 1 | 2018-11-19 | The purpose of this study is to determine the effect of treatment with guselkumab in participants with familial adenomatous polyposis (FAP) on rectal/pouch polyp burden. |
| NCT03818035 ↗ | A Study to Evaluate Further Therapeutic Strategies With Guselkumab in Participants With Moderate-to-Severe Plaque-Type Psoriasis | Active, not recruiting | Janssen-Cilag G.m.b.H | Phase 3 | 2019-02-08 | The purpose of this study is to demonstrate that Super-Responders (SRe; defined as psoriasis participants who receive on-label guselkumab treatment until week 20 and respond with a Psoriasis Area and Severity Index score (PASI) = 0 at weeks 20 and 28) maintain control of disease until week 68 with prolonged treatment intervals of 16 weeks (guselkumab 100 mg every 16 weeks). |
| NCT04340076 ↗ | Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis | Recruiting | Belgium Health Care Knowledge Centre | Phase 4 | 2020-08-20 | The main objective of this study is to investigate whether controlled dose reduction of IL17 or IL23 inhibiting biologics is not inferior compared to usual care in psoriasis patients. Therefore, a pragmatic, multicentre, randomized, controlled, non-inferiority study will be carried out. |
| NCT04340076 ↗ | Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis | Recruiting | University Hospital, Ghent | Phase 4 | 2020-08-20 | The main objective of this study is to investigate whether controlled dose reduction of IL17 or IL23 inhibiting biologics is not inferior compared to usual care in psoriasis patients. Therefore, a pragmatic, multicentre, randomized, controlled, non-inferiority study will be carried out. |
| NCT04340076 ↗ | Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis | Recruiting | ZonMw: The Netherlands Organisation for Health Research and Development | Phase 4 | 2020-08-20 | The main objective of this study is to investigate whether controlled dose reduction of IL17 or IL23 inhibiting biologics is not inferior compared to usual care in psoriasis patients. Therefore, a pragmatic, multicentre, randomized, controlled, non-inferiority study will be carried out. |
| NCT04340076 ↗ | Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis | Recruiting | Radboud University | Phase 4 | 2020-08-20 | The main objective of this study is to investigate whether controlled dose reduction of IL17 or IL23 inhibiting biologics is not inferior compared to usual care in psoriasis patients. Therefore, a pragmatic, multicentre, randomized, controlled, non-inferiority study will be carried out. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for TREMFYA
Condition Name
Clinical Trial Locations for TREMFYA
Trials by Country
Clinical Trial Progress for TREMFYA
Clinical Trial Phase
Clinical Trial Sponsors for TREMFYA
Sponsor Name
